Nanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria
July 12 2021 - 7:00AM
Business Wire
Making its first steps in West Africa, Nanox
partners with EiLEENO Pharma to make medical imaging accessible and
available across Nigeria to both public and private medical
institutions
NANO-X IMAGING LTD ("Nanox" or the "Company,"
Nasdaq: NNOX), an innovative medical imaging company, enters the
West African market, signing an exclusive distribution deal with
EiLEENO Pharma to deploy Nanox's medical imaging services in
Nigeria.
The Nanox System is composed of the Nanox.ARC, a medical imaging
system incorporating a novel digital X-ray source, and the
Nanox.CLOUD, a companion cloud-based software designed to provide
an end-to-end medical imaging service that is expected to include
image repository, radiologist matching, online and offline
diagnostics review and annotation, connectivity to diagnostic
assistive artificial intelligence systems, billing, and
reporting.
Subject to regulatory approval, Nanox and EiLEENO Pharma will
collaborate on the deployment and operation of 1,000 Nanox Systems
comprised of the Nanox.ARC and the Nanox.CLOUD; all designated to
improve the standard of care in Nigeria via significantly increased
availability of medical imaging for the benefit of patients across
the country.
According to the agreement and subject to regulatory approval,
EiLEENO Pharma will commit to a minimum annual service fee to
Nanox. The agreement has an initial term of four years and is
renewable for an additional term of four years with both parties’
mutual consent.
"We are very excited to sign the unique MSaaS agreement with
NANOX, to deploy medical imaging systems and ensure services for
healthcare facilities across the country," said Edward Egede,
Managing Director and CEO of EiLEENO Pharma.
"This will drive affordability of medical imaging in Africa
towards the goal that each Nigerian carries out comprehensive
medical checks at least once a year to proactively manage their
health and help promote preventive healthcare. Our broad spread of
nearly 4,400 health facilities in Nigeria, covers populations in
various geographic areas, especially those who are remotely
habited.”
According to the World Health Organization (WHO) approximately
two-thirds of the world's population does not have access to
medical imaging systems, while many people with access to medical
imaging face substantial wait times for scanning. Medical imaging
systems are an important early-detection tool that Nanox believes
are key to increasing early treatment, improving health outcomes,
and ultimately saving lives.
"West Africa is one of the prime target markets for us," says
Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "The
agreement with EiLEENO Pharma will allow us to support Nigeria's
population, enabling the nation to run high-volume screening
campaigns cross-country. We want medical imaging to become as
commonplace and accessible as water or electricity, readily
available to all communities everywhere."
About Nanox: Nanox, founded by the serial entrepreneur
Ran Poliakine, is an Israeli corporation developing a
commercial-grade digital X-ray source designed to be used in
real-world medical imaging applications. Nanox believes that its
novel technology could significantly reduce the costs of medical
imaging systems and plans to seek collaborations with world-leading
healthcare organizations and companies to provide affordable, early
detection imaging services for all. For more information, please
visit www.nanox.vision.
About EiLEENO Pharma Founded in Nigeria in 2018, EiLEENO
Pharma Ltd is a leading manufacturer and distributor of medical
supplies and equipment in the country, supplying such essentials as
medical oxygen and other gases and medical imaging equipment. The
company offers its customers comprehensive distribution services,
including procurement, warehousing, and inventory management. It is
one of the most vocal supporters of raising healthcare awareness
among Nigerian communities and arming them with all the essentials
that they need to maintain a high quality of health services. For
more information, please visit https://epl.com.ng/
Forward-Looking Statements This press release may contain
forward-looking statements that are subject to risks and
uncertainties. All statements that are not historical facts
contained in this press release are forward-looking statements.
Such statements include, but are not limited to, any statements
relating to the initiation, timing, progress, and results of
Nanox's research and development, manufacturing, and
commercialization activities with respect to its X-ray source
technology and the Nanox.Arc. In some cases, you can identify
forward-looking statements by terminology such as "can," "might,"
"believe," "may," “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “should,” “could,” “expect,” “predict,”
“potential,” or the negative of these terms or other similar
expressions. Forward-looking statements are based on information
Nanox has when those statements are made or management's good faith
belief as of that time with respect to future events, and are
subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in
or suggested by the forward-looking statements. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks related to Nanox's ability to complete
development of the Nanox.Arc ; Nanox's ability to successfully
demonstrate the feasibility of its technology for commercial
applications; Nanox's expectations regarding the necessity of,
timing of filing for, and receipt and maintenance of, regulatory
clearances or approvals regarding its X-ray source technology and
the Nanox.Arc from regulatory agencies worldwide and its ongoing
compliance with applicable quality standards and regulatory
requirements; Nanox's ability to enter into and maintain
commercially reasonable arrangements with third-party manufacturers
and suppliers to manufacture the Nanox.Arc; the market acceptance
of the Nanox.Arc and the proposed pay-per-scan business model;
Nanox's expectations regarding collaborations with third-parties
and their potential benefits; and Nanox's ability to conduct
business globally, among others. Except as required by law, Nanox
undertakes no obligation to update publicly any forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Nanox's
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210712005384/en/
Media Contact: Alona Stein ReBlonde for Nanox
alona@reblonde.com
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From Apr 2023 to Apr 2024